Cancer Disease-Oriented-Drug Development Examples

Autores
Gandia, Daniel Enrique; Suárez, Cecilia Ana
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The history of cancer medical treatments goes up to 1908 with the use of arsenic in this disease. An intermediate milestone was the discovery, in 1943, of an amazing tumor response using nitrogen mustard in a patient with a radio-resistant lymphoma. Chemotherapy really born with this achievement, and a plethora of antitumor agent’s came to age after 1948 till nowadays. Here, some examples of recent disease-oriented drug development approaches are presented and analyzed, as well as present limitations and challenges raised by each one.
Fil: Gandia, Daniel Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física del Plasma. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física del Plasma; Argentina
Fil: Suárez, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física del Plasma. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física del Plasma; Argentina
Materia
CANCER
NEOPLASMS
CHEMOTHERAPY
ANTITUMOR AGENTS
DRUG DEVELOPMENT
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/214880
Acceder
id CONICETDig_cc16ba46edfb54c77dad57eedab7ac34
oai_identifier_str oai:ri.conicet.gov.ar:11336/214880
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Cancer Disease-Oriented-Drug Development ExamplesGandia, Daniel EnriqueSuárez, Cecilia AnaCANCERNEOPLASMSCHEMOTHERAPYANTITUMOR AGENTSDRUG DEVELOPMENThttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3The history of cancer medical treatments goes up to 1908 with the use of arsenic in this disease. An intermediate milestone was the discovery, in 1943, of an amazing tumor response using nitrogen mustard in a patient with a radio-resistant lymphoma. Chemotherapy really born with this achievement, and a plethora of antitumor agent’s came to age after 1948 till nowadays. Here, some examples of recent disease-oriented drug development approaches are presented and analyzed, as well as present limitations and challenges raised by each one.Fil: Gandia, Daniel Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física del Plasma. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física del Plasma; ArgentinaFil: Suárez, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física del Plasma. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física del Plasma; ArgentinaOpenventio Publishers2022-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/214880Gandia, Daniel Enrique; Suárez, Cecilia Ana; Cancer Disease-Oriented-Drug Development Examples; Openventio Publishers; Cancer Studies and Molecular Medicine; 7; 1; 10-2022; 1-22377-1518CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://openventio.org/wp-content/uploads/Cancer-Disease-Oriented-Drug-Development-Examples-CSMMOJ-7-132.pdfinfo:eu-repo/semantics/altIdentifier/doi/10.17140/CSMMOJ-7-132info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:54Zoai:ri.conicet.gov.ar:11336/214880instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:55.122CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Cancer Disease-Oriented-Drug Development Examples
title Cancer Disease-Oriented-Drug Development Examples
spellingShingle Cancer Disease-Oriented-Drug Development Examples
Gandia, Daniel Enrique
CANCER
NEOPLASMS
CHEMOTHERAPY
ANTITUMOR AGENTS
DRUG DEVELOPMENT
title_short Cancer Disease-Oriented-Drug Development Examples
title_full Cancer Disease-Oriented-Drug Development Examples
title_fullStr Cancer Disease-Oriented-Drug Development Examples
title_full_unstemmed Cancer Disease-Oriented-Drug Development Examples
title_sort Cancer Disease-Oriented-Drug Development Examples
dc.creator.none.fl_str_mv Gandia, Daniel Enrique
Suárez, Cecilia Ana
author Gandia, Daniel Enrique
author_facet Gandia, Daniel Enrique
Suárez, Cecilia Ana
author_role author
author2 Suárez, Cecilia Ana
author2_role author
dc.subject.none.fl_str_mv CANCER
NEOPLASMS
CHEMOTHERAPY
ANTITUMOR AGENTS
DRUG DEVELOPMENT
topic CANCER
NEOPLASMS
CHEMOTHERAPY
ANTITUMOR AGENTS
DRUG DEVELOPMENT
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The history of cancer medical treatments goes up to 1908 with the use of arsenic in this disease. An intermediate milestone was the discovery, in 1943, of an amazing tumor response using nitrogen mustard in a patient with a radio-resistant lymphoma. Chemotherapy really born with this achievement, and a plethora of antitumor agent’s came to age after 1948 till nowadays. Here, some examples of recent disease-oriented drug development approaches are presented and analyzed, as well as present limitations and challenges raised by each one.
Fil: Gandia, Daniel Enrique. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física del Plasma. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física del Plasma; Argentina
Fil: Suárez, Cecilia Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Física del Plasma. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Física del Plasma; Argentina
description The history of cancer medical treatments goes up to 1908 with the use of arsenic in this disease. An intermediate milestone was the discovery, in 1943, of an amazing tumor response using nitrogen mustard in a patient with a radio-resistant lymphoma. Chemotherapy really born with this achievement, and a plethora of antitumor agent’s came to age after 1948 till nowadays. Here, some examples of recent disease-oriented drug development approaches are presented and analyzed, as well as present limitations and challenges raised by each one.
publishDate 2022
dc.date.none.fl_str_mv 2022-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/214880
Gandia, Daniel Enrique; Suárez, Cecilia Ana; Cancer Disease-Oriented-Drug Development Examples; Openventio Publishers; Cancer Studies and Molecular Medicine; 7; 1; 10-2022; 1-2
2377-1518
CONICET Digital
CONICET
url http://hdl.handle.net/11336/214880
identifier_str_mv Gandia, Daniel Enrique; Suárez, Cecilia Ana; Cancer Disease-Oriented-Drug Development Examples; Openventio Publishers; Cancer Studies and Molecular Medicine; 7; 1; 10-2022; 1-2
2377-1518
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://openventio.org/wp-content/uploads/Cancer-Disease-Oriented-Drug-Development-Examples-CSMMOJ-7-132.pdf
info:eu-repo/semantics/altIdentifier/doi/10.17140/CSMMOJ-7-132
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Openventio Publishers
publisher.none.fl_str_mv Openventio Publishers
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613083373240320
score 13.070432

Publicaciones similares